Unternehmensübersicht
Tvardi Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of novel, oral, and small molecule therapies that specifically target signal transducer and activator of transcription 3 (STAT3) for the treatment of inflammatory and proliferative diseases. The company functions within the broader healthcare sector, specifically inside the biotechnology industry, positioning itself to address significant unmet medical needs through proprietary therapeutic mechanisms. As of the latest available data, the firm maintains a market capitalization of $28.61M and employs a workforce of 12 individuals to advance its research and development initiatives. The current market cap of $28.61M reflects the company's status as a micro-cap entity with limited revenue generation, indicating a business model heavily reliant on capital markets for funding rather than organic cash flow from sales.
Finanzielle Gesundheit
Tvardi Therapeutics, Inc. reports no revenue for the trailing twelve months (TTM), resulting in a net income of $-18,214,000 and an EBITDA of $-26,653,000. The absence of revenue combined with substantial net losses reveals a cost structure dominated by research, development, and operational expenses typical of early-stage biotechnology firms that have not yet achieved commercial product launch. The company generated free cash flow of $-15,216,500, which indicates a negative financial flexibility where cash reserves are being consumed to fund operations and scientific advancement rather than generating surplus liquidity. All three reported margins—gross margin at 0.0%, operating margin at 0.0%, and profit margin at 0.0%—underscore the pre-revenue nature of the business where traditional profitability metrics are not applicable due to the lack of sales activity. The balance sheet holds $30.81M in cash against $201,000 in debt, resulting in a debt-to-equity ratio of 0.96, which suggests a relatively conservative leverage profile despite the high cash holdings relative to liabilities. Liquidity is further supported by a current ratio of 2.86, indicating that the company possesses more than double the current assets necessary to cover its short-term obligations. Return on Equity stands at -237.8% while Return on Assets is -49.7%, metrics that mathematically reflect the heavy investment phase where shareholder equity and total assets are being eroded by operating losses rather than generating returns.
Bewertungsanalyse
The valuation metrics for Tvardi Therapeutics, Inc. show a P/E Ratio (TTM) of N/A due to the lack of earnings, while the Forward P/E is listed at -1.17, implying that future earnings estimates are currently negative or insufficient to form a traditional trailing multiple. The Price to Book ratio is 1.37, suggesting that the market values the company at approximately 37% above its net asset book value, which can indicate either a premium for intangible assets like intellectual property or market speculation on future pipeline potential. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of 0.07, which highlights the extreme sensitivity of the valuation to future commercial success rather than current cash flow generation. The stock trades within a range defined by a 52-week high of $43.65 and a 52-week low of $2.81, demonstrating extreme volatility and a wide trading band typical of speculative biotechnology stocks. The beta value is N/A, meaning that standard volatility relative to the broader market cannot be quantified with the provided data, yet the massive swing between the yearly high and low suggests high sensitivity to market sentiment and clinical trial news.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet generated commercial sales to establish a growth trajectory or historical earnings base for comparison. Because the company has not yet reached a profitable stage, there are no dividends paid, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means all available cash flow is theoretically available for reinvestment into research and development rather than distribution to shareholders. The company reinvests its existing cash reserves entirely into its clinical-stage pipeline to pursue regulatory approvals and market entry, foregoing any current income generation to prioritize long-term asset creation. The overall growth and income profile is characterized by a complete absence of current financial returns and historical growth rates, relying entirely on the successful execution of its STAT3-targeting therapeutic pipeline to transition from a cash-burning entity to a revenue-generating business in the future.